Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:51 UTC |
---|
HMDB ID | HMDB0015087 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Naratriptan |
---|
Description | Naratriptan, also known as naramig or amerge, belongs to the class of organic compounds known as 3-alkylindoles. 3-alkylindoles are compounds containing an indole moiety that carries an alkyl chain at the 3-position. It was covered by U.S. Patent no. 4997841; the FDA lists the patent as expiring on July 7, 2010. Naratriptan is a drug which is used for the acute treatment of migraine attacks with or without aura in adults. Side-effects which are unlikely and which should be promptly reported include: chest pain/pressure, throat pain/pressure, unusually fast/slow/irregular pulse, one-sided muscle weakness, vision problems, cold/bluish hands or feet, stomach pain, bloody diarrhea, mental/mood changes, and fainting. Because Teva and Sandoz are the only approved suppliers of generic Naratriptan in Canada, the quarantine resulted in Naratriptan being placed on the Canadian drug shortage list. Naratriptan is a very strong basic compound (based on its pKa). Naratriptan is a potentially toxic compound. Naratriptan is used for the treatment of the acute migraine attacks and the symptoms of migraine, including severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light. Symptoms of a serious allergic reaction include: rash, itching, swelling, severe dizziness, trouble breathing (swelling of the throat). In July 2010, in the wake of the patent expiration, several drug manufacturers, including Roxane Labs, Sandoz and Teva Pharmaceuticals, announced that they were launching generic Naratriptan medications. A meta-analysis of 53 clinical trials has shown that all triptans are effective for treating migraine at marketed doses and that naratriptan, although less effective than sumatriptan and rizatriptan was more effective than placebo in reducing migraine symptoms at two hours and efficacy was demonstrated in almost two thirds of subjects after four hours of treatment. Naratriptan (trade names include Amerge) is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. It had previously been covered by Canadian patent 1210968; but both Sandoz and Teva (formerly Novopharm) have offered generic equivalents in Canada since that patent's expiration December 1, 2009. |
---|
Structure | CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1 InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 |
---|
Synonyms | Value | Source |
---|
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide | ChEBI | N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide | ChEBI | Naratriptanum | ChEBI | Naramig | Kegg | N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulphonamide | Generator | N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulphonamide | Generator | Faes brand OF naratriptan hydrochloride | HMDB | Amerge | HMDB | Colatan | HMDB | Glaxo wellcome brand OF naratriptan hydrochloride | HMDB | GlaxoSmithKline brand OF naratriptan hydrochloride | HMDB | Schwarz brand OF naratriptan hydrochloride | HMDB | Naratriptan hydrochloride | HMDB | N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide | HMDB | N-Methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride | HMDB | 1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride | HMDB |
|
---|
Chemical Formula | C17H25N3O2S |
---|
Average Molecular Weight | 335.464 |
---|
Monoisotopic Molecular Weight | 335.166747749 |
---|
IUPAC Name | N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethane-1-sulfonamide |
---|
Traditional Name | naratriptan |
---|
CAS Registry Number | 121679-13-8 |
---|
SMILES | CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1 |
---|
InChI Identifier | InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 |
---|
InChI Key | AMKVXSZCKVJAGH-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 3-alkylindoles. 3-Alkylindoles are compounds containing an indole moiety that carries an alkyl chain at the 3-position. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Indoles and derivatives |
---|
Sub Class | Indoles |
---|
Direct Parent | 3-alkylindoles |
---|
Alternative Parents | |
---|
Substituents | - 3-alkylindole
- Aralkylamine
- Piperidine
- Substituted pyrrole
- Organic sulfonic acid amide
- Benzenoid
- Organosulfonic acid amide
- Pyrrole
- Organic sulfonic acid or derivatives
- Heteroaromatic compound
- Organosulfonic acid or derivatives
- Aminosulfonyl compound
- Sulfonyl
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organosulfur compound
- Organonitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 246 °C (hydrochloride salt) | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.11 g/L | Not Available | LogP | 1.6 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 174.3 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Naratriptan,1TMS,isomer #1 | CN1CCC(C2=C[NH]C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C)C=C23)CC1 | 3126.2 | Semi standard non polar | 33892256 | Naratriptan,1TMS,isomer #1 | CN1CCC(C2=C[NH]C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C)C=C23)CC1 | 2973.1 | Standard non polar | 33892256 | Naratriptan,1TMS,isomer #1 | CN1CCC(C2=C[NH]C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C)C=C23)CC1 | 3881.8 | Standard polar | 33892256 | Naratriptan,1TMS,isomer #2 | CNS(=O)(=O)CCC1=CC=C2C(=C1)C(C1CCN(C)CC1)=CN2[Si](C)(C)C | 3027.5 | Semi standard non polar | 33892256 | Naratriptan,1TMS,isomer #2 | CNS(=O)(=O)CCC1=CC=C2C(=C1)C(C1CCN(C)CC1)=CN2[Si](C)(C)C | 2926.4 | Standard non polar | 33892256 | Naratriptan,1TMS,isomer #2 | CNS(=O)(=O)CCC1=CC=C2C(=C1)C(C1CCN(C)CC1)=CN2[Si](C)(C)C | 4002.1 | Standard polar | 33892256 | Naratriptan,2TMS,isomer #1 | CN1CCC(C2=CN([Si](C)(C)C)C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C)C=C23)CC1 | 3118.1 | Semi standard non polar | 33892256 | Naratriptan,2TMS,isomer #1 | CN1CCC(C2=CN([Si](C)(C)C)C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C)C=C23)CC1 | 3105.9 | Standard non polar | 33892256 | Naratriptan,2TMS,isomer #1 | CN1CCC(C2=CN([Si](C)(C)C)C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C)C=C23)CC1 | 3737.6 | Standard polar | 33892256 | Naratriptan,1TBDMS,isomer #1 | CN1CCC(C2=C[NH]C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C(C)(C)C)C=C23)CC1 | 3304.5 | Semi standard non polar | 33892256 | Naratriptan,1TBDMS,isomer #1 | CN1CCC(C2=C[NH]C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C(C)(C)C)C=C23)CC1 | 3251.9 | Standard non polar | 33892256 | Naratriptan,1TBDMS,isomer #1 | CN1CCC(C2=C[NH]C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C(C)(C)C)C=C23)CC1 | 3938.6 | Standard polar | 33892256 | Naratriptan,1TBDMS,isomer #2 | CNS(=O)(=O)CCC1=CC=C2C(=C1)C(C1CCN(C)CC1)=CN2[Si](C)(C)C(C)(C)C | 3211.5 | Semi standard non polar | 33892256 | Naratriptan,1TBDMS,isomer #2 | CNS(=O)(=O)CCC1=CC=C2C(=C1)C(C1CCN(C)CC1)=CN2[Si](C)(C)C(C)(C)C | 3167.4 | Standard non polar | 33892256 | Naratriptan,1TBDMS,isomer #2 | CNS(=O)(=O)CCC1=CC=C2C(=C1)C(C1CCN(C)CC1)=CN2[Si](C)(C)C(C)(C)C | 4064.5 | Standard polar | 33892256 | Naratriptan,2TBDMS,isomer #1 | CN1CCC(C2=CN([Si](C)(C)C(C)(C)C)C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C(C)(C)C)C=C23)CC1 | 3476.7 | Semi standard non polar | 33892256 | Naratriptan,2TBDMS,isomer #1 | CN1CCC(C2=CN([Si](C)(C)C(C)(C)C)C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C(C)(C)C)C=C23)CC1 | 3609.4 | Standard non polar | 33892256 | Naratriptan,2TBDMS,isomer #1 | CN1CCC(C2=CN([Si](C)(C)C(C)(C)C)C3=CC=C(CCS(=O)(=O)N(C)[Si](C)(C)C(C)(C)C)C=C23)CC1 | 3814.3 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Naratriptan GC-MS (Non-derivatized) - 70eV, Positive | splash10-0563-6592000000-ddbcdc8fb1564ab67954 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Naratriptan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Naratriptan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 10V, Positive-QTOF | splash10-0079-0019000000-6a6e24b9a465404217cb | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 20V, Positive-QTOF | splash10-052f-5196000000-d65d77c315f42655bc94 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 40V, Positive-QTOF | splash10-00dj-9181000000-5426adb0583eefe0387d | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 10V, Negative-QTOF | splash10-001i-2009000000-94e23cf10a35640e1665 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 20V, Negative-QTOF | splash10-056r-9047000000-e204b450ea7d67367377 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 40V, Negative-QTOF | splash10-03fu-9010000000-4168e596b68161b1f564 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 10V, Positive-QTOF | splash10-000i-0009000000-eb77fa3eb994fd4f881e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 20V, Positive-QTOF | splash10-03di-0091000000-3e0656c2932e26031087 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 40V, Positive-QTOF | splash10-001j-8974000000-f06f269baa785ea29ed4 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 10V, Negative-QTOF | splash10-001i-0009000000-0fe6fb135327a243d85b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 20V, Negative-QTOF | splash10-001l-1096000000-9e82cb949d18ff9c097d | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Naratriptan 40V, Negative-QTOF | splash10-0200-2091000000-28483e9f079277138f81 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|